Pfizer invests nearly US$100 million in Valneva to accelerate Lyme disease vaccine
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Pfizer invests nearly US$100 million in Valneva to accelerate Lyme disease vaccine
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Pfizer invests nearly US$100 million in Valneva to accelerate the development of the world’s first new Lyme disease vaccine.
After disclosing positive Phase II data for VLA15 in children (VLA15-221) two months ago, Pfizer and Valneva decided to deepen their collaboration.
Earlier this week (June 20), Pfizer announced that it would acquire an 8.1% stake in French vaccine company Valneva at a price of 9.49 euros per share, for a total consideration of 90.5 million euros (about 95.24 million U.S. dollars).
The deal will close by June 22, and Valneva plans to use the proceeds to support the Phase III clinical development of VLA15.
Pfizer and Valneva also renewed the collaboration agreement signed in April 2020.
The two previously agreed that Valneva will bear 30% of the development cost of VLA15, and after this revision, this proportion will be increased to 40%.
At the same time, Pfizer will also pay Valneva’s tiered royalties from 19% to 14% to 22%.
If the product is eventually approved, Pfizer will also pay Valneva up to $100 million in milestone payments based on cumulative sales.
Other development and early commercialization milestones have not changed, including the $25 million Pfizer will pay Valneva when VLA15 initiates a Phase III clinical trial.
For now, Valneva is expected to get the proceeds this year.
(source:internet, reference only)
Disclaimer of medicaltrend.org
